Former FDA Head Kessler Suggests Alternate Safety Monitoring Route
This article was originally published in The Tan Sheet
Executive Summary
FDA needs to reevaluate its premarket review process of drugs for non-life-threatening conditions, according to former Commissioner David Kessler, MD
You may also be interested in...
Vioxx Hearing Witnesses Push For Independent Drug Safety Office
The proposal to create an independent Office of Drug Safety at FDA may be gaining momentum, following a congressional hearing reviewing FDA's handling of Merck's Vioxx (rofecoxib)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands